Japan Tissue Engineering Co., Ltd. Reports Non-Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Earnings Guidance for the Full Year Ending March 31, 2019
October 30, 2018 at 12:00 pm IST
Share
Japan Tissue Engineering Co., Ltd. reported non-consolidated earnings results for the six months Ended September 30, 2018. For the period, the company reported net sales of JPY 1,023 million against JPY 1,090 million a year ago. Operating loss was JPY 423 million against income of JPY 84 million a year ago. Ordinary loss was JPY 418 million against income of JPY 84 million a year ago. Net loss was JPY 415 million against income of JPY 67 million a year ago. Net loss per share was JPY 10.23 against income of JPY 1.65 a year ago.
For the full year ending March 31, 2019, the company expects to report, sales of JPY 3,080 million, operating loss JPY 49 million, ordinary loss JPY 42 million and net loss JPY 53 million or net loss per share JPY 1.32.
Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.
Japan Tissue Engineering Co., Ltd. Reports Non-Consolidated Earnings Results for the Six Months Ended September 30, 2018; Provides Earnings Guidance for the Full Year Ending March 31, 2019